[go: up one dir, main page]

WO1996009062A1 - Agonistes et antagonistes polypeptidiques de l'interleukine-8 humaine - Google Patents

Agonistes et antagonistes polypeptidiques de l'interleukine-8 humaine Download PDF

Info

Publication number
WO1996009062A1
WO1996009062A1 PCT/US1995/012099 US9512099W WO9609062A1 WO 1996009062 A1 WO1996009062 A1 WO 1996009062A1 US 9512099 W US9512099 W US 9512099W WO 9609062 A1 WO9609062 A1 WO 9609062A1
Authority
WO
WIPO (PCT)
Prior art keywords
cys
lys
leu
xaa
sequence
Prior art date
Application number
PCT/US1995/012099
Other languages
English (en)
Inventor
James E. Talmadge
Original Assignee
University Of Nebraska Board Of Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/311,307 external-priority patent/US5627156A/en
Application filed by University Of Nebraska Board Of Regents filed Critical University Of Nebraska Board Of Regents
Priority to AU36817/95A priority Critical patent/AU3681795A/en
Publication of WO1996009062A1 publication Critical patent/WO1996009062A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5421—IL-8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to polypeptide analogs of the human cytokine interleukin 8 that function as agonists or antagonists of interleukin 8 and other human alpha chemokines.
  • the invention also provides methods of using these peptide analogs to augment or inhibit various biological responses associated with alpha chemokines.
  • Interleukin 8 is a human cytokine that promotes the recruitment and activation of neutrophil leukocytes and represents one of several endogenous mediators of the acute inflammatory response. In the past it was variously termed neutrophil-activating factor, monocyte-derived neutrophil chemotactic factor, interleukin-8 (IL-8) , and neutrophil-activating peptide- 1, (NAP-1) .
  • the term IL-8 has gained the widest acceptance and will be used herein.
  • IL-8 monomer The most abundant naturally occurring form of the IL-8 monomer is a 72-residue protein apparently derived by processing of a 99-residue precursor.
  • Other proteins with related sequences, including neutrophil- activating peptide-2 and GROCK (with melanoma growth stimulatory activity) are IL-8 homologues which have neutrophil-activating properties.
  • IL-8 is a member of the chemokine superfamily that is divided into two distinct functional classes: alpha (o.) and beta (3) .
  • the members of each class share an organizing primary sequence motif.
  • the a members are distinguished by a C-X-C motif with the first two cysteines in the motif separated by an intervening residue.
  • C-X-C chemokines are potent chemoattractants and activators for neutrophils, and are represented by IL-8.
  • the jS family chemokines have a C-C motif and are equally potent chemoattractants and activators of monocytes.
  • chemokine family has clearly defined functions: the C- X-C subfamilies cannot activate monocytes while the C-C subfamily has no effect on neutrophils. Although these two families of chemokines have similar three dimensional structures, they demonstrate fairly low sequence homology (30 to 35%) . Proteins within the same family, such as platelet factor four (PP-4) , are structurally related to IL-8 (35% sequence identity) but lack the N terminal ELR sequence (Glu-Leu-Arg) which has been shown by site directed mutagenesis to be critical for IL-8 activity. Thus, PF-4 has an entirely different profile of biological activity.
  • PP-4 platelet factor four
  • Inflammation and autoimmune responses are initiated by leukocytes which migrate out of the microvasculature and into the extravascular space in response to chemoattractant molecules.
  • chemoattractants may be released from the host and include cytokines and activated complement components. Alternatively, they may be released from an invading organism (e.g., N-formylated peptides or MDP dipeptide) . Once exposed to chemoattractants within the vasculature, the leukocytes become activated and capable of adhering to the endothelium, providing the first step in the development of inflammation.
  • Stimulated neutrophils adhere to the endothelium of the microvasculature in response to a gradient of chemoattractants which direct the cells into the extravascular space toward the source of the chemoattractant.
  • the endothelium After stimulation with cytokines or bacterial products, the endothelium arrests leukocytes as they traverse (roll along) the microvasculature near sites of inflammation. After being forced to stop in the microvasculature, the leukocytes are then activated to adhere more tightly to the endothelium and to migrate to the abluminal aspect of the vessel. The leukocyte, once it is out of the blood vessel, is then capable of following a gradient of chemoattractants toward the exciting pathogen.
  • Vascular endothelium activated by stimulants such as IL-1, IL-8, TNF, or LPS, appears to play a pivotal role in this process through the production of pro-inflammatory substances, including chemoattractants and cytokines such as chemokines.
  • the inflammatory properties of IL-8 were initially demonstrated from a purified natural product injected intradermally into rabbits (Rampart, M. et al. , Am. J. Path. 125. (1) :21-25, 1989) . More recently, neutralizing antibodies to human IL-8 were shown to have a protective effect in inflammatory lung injury in rats.
  • neutrophilia Shortly thereafter neutrophilia, a characteristic of IL- 8, is observed.
  • the neutrophilia likely reflects recruitment of mature PMNs to a marginal pool in the lung and other organs as well as immature PMNs from the marrow.
  • Endothelial cells can exert both proinflammatory and anti-inflammatory effects by virtue of the mediators they generate. Endothelial cells can be stimulated to generate IL-8, but unlike other mediators, IL-8 may be released from the endothelial cell. Alternatively, endothelial cell produced IL-8 is an important chemoattractant and activator of neutrophils .
  • IL-8 can bind to endothelial cells, causing a local activation of the endothelium that results in the ability of this altered endothelium to attract neutrophils that have come into contact with the (activated) endothelium.
  • IL-8 initially functions as a proinflammatory cytokine, whereas its continued generation and release from the endothelium ultimately causes a down regulation of neutrophils, with a curtailment in their further recruitment. Whether the cell associated IL-8 or released IL-8 provides the vital contribution to the outcome of the inflammatory response remains unresolved.
  • IL-8 receptors are "promiscuous" and respond with a calcium flux when bound by structurally related ligands with the following order of potency: IL-8 > MGSA > NAP-2. The order of potency correlates with the effectiveness of these compounds in binding to neutrophils during competitive binding assays with the radio-labeled IL-8.
  • C5a a structurally related chemoattractant that is similar in size and charge to IL- 8 and which has a receptor in the same family, does not activate the IL-8 receptor.
  • IL-8 appears to bind to at least one class of receptor sites on neutrophils with a frequency of approximately 64,000/cell and a K ⁇ , of 0.2 nM.
  • IL-8 The three-dimensional structure of IL-8 is known by two-dimensional NMR and x-ray diffraction techniques.
  • the IL-8 monomer has antiparallel ⁇ strands followed by a single overlying COOH-terminal ⁇ ; helix.
  • Two disulfide bridges, between cysteines 7 and 34, and between cysteines 9 and 50 seem to stabilize the tertiary structure.
  • Residues 1-6 and the loop residues 7-18 seem to have little defined secondary structure.
  • IL-8 is a noncovalent homodimer which is stabilized primarily by interactions between the ⁇ strands of the two monomers.
  • Interleukin-8 has shown both anti-tumor and anti-infective therapeutic activity. IL-8 has been shown to induce the regression of macroscopic tumors in a model of peritoneal carcinomatosis in the rat. In this model, IL-8 was shown to recruit PMN to the challenge site but did not enhance PMN infiltration of the tumor or the cytotoxic activity of PMN. Regardless, it did have significant therapeutic activity which may be secondary to PMN cytotoxicity and associated with other intermediate cells. It is suggested that lymphocytes could be involved since IL-8 has also demonstrated the ability to stimulate T-cell chemotaxis. (Lejeune, P., et al. , Cancer Immunol. Immunotherapy. 3.8:167-170, 1994). Similarly, Interleukin-8 has shown therapeutic activity in nonneutropenic mice who received IL-8 shortly before challenge and at the site of infectious challenge with either P. aeruginosa, Klebsiella -pneumoniae, or
  • IP-10 an alpha chemokine whose secretion is induced by IFN- ⁇ and LPS, was genetically engineered into tumor cells.
  • the expression of IP-10 by several tumor cell lines had no effect on the growth of these tumor cells in vi tro but elicited a powerful host mediated anti-tumor effect in vivo.
  • tumors genetically engineered to secrete IP-10 elicited a T-lymphocyte dependent anti-tumor response resulting in the rejection of tumors in vivo. Animals injected with these tumor cells do not develop tumors or develop tumors which spontaneously regress.
  • administration of parental tumor cells admixed with IP-10 secreting tumor cells do not give rise to tumors in experimental animals.
  • alpha chemokines may also act as T-cell adjuvants and therapeutics via T-cell chemotaxis and/or augmentation (Luster, A.D., J..Exp. Med. 178.:1057-1064, 1993). Because of its demonstrated anti-tumor and anti-infective activities, considerable interest exists in developing specific IL-8 agonists as immune adjuvants and anti-tumor agents for treatment of immunocompromised patients or patients with various forms of cancer.
  • One strategy for developing agonists is to prepare polypeptide analogs which correspond to the known or suspected binding domains of naturally occurring IL-8 and related alpha chemokines. Such analogs are often found capable not only of binding to a cognate receptor, but of stimulating a desired biological response, such as anti- tumor activity for IL-8.
  • IL-8 is also a key mediator of inflammatory diseases
  • substances capable of blocking or interrupting the activity of IL-8 for use in anti- inflammatory compositions may prove to be advantageous over presently available NSAID's, steroid based anti-inflammatory drugs and cytotoxic drugs which often have severe side-effects with the continued usage that is required for chronic inflammatory diseases. It would also be desirable to identify IL-8 analogs having an increased inflammatory activity for medical research applications.
  • IL-8 has been previously produced through chemical synthesis (Clark-Lewis, et al. , Biochemistry 30: 3128-3135, 1991) and by recombinant DNA methods (Herbert, et al., J. Biol. Chem. 286: 18989-18994, 1991).
  • IL-8 exists in several forms that vary at the NH 2 -terminus, which have been detected in preparations purified from natural sources.
  • the present invention involves low molecular weight peptides which have agonistic or antagonistic activity for IL-8 or other alpha chemokines.
  • the peptide agonists have an amino acid sequence with the following formula:
  • Xaa 2 is lie, or Val;
  • Xaa 3 is Lys, Gin, or Ser;
  • Xaa 4 is Thr, or lie;
  • Xaa 5 is Tyr, Leu, Met, His, Val, or Thr;
  • Xaa 6 is Ser, Gin, Thr, or Ala;
  • Xaa 7 is Lys, Arg, or His;
  • Xaa 8 is absent or is Pro, Phe, or Gly;
  • Xaa 9 is absent or is Phe, lie, or Val;
  • Xaa 10 is absent or is His, Lys, or Arg;
  • Xaa ⁇ is absent or is Pro, Leu, or Phe; and Xaa 12 is absent or is Lys, His or Arg.
  • a preferred embodiment of the present invention comprises an amino acid sequence with agonist activity substantially equivalent to Glu- Leu-Arg-Cys-Gln-Cys-Ile-Lys-Thr-Tyr-Ser-Lys-Pro-Phe-His- Pro-Lys as well as similar analogs having additional N- terminal amino acids.
  • These polypeptides act as anti- cancer and anti-infective agents for the therapy of leukemia and solid tumors and metastatic disease.
  • These embodiments also have anti-infective therapeutic activity for viral, bacterial, fungal, yeast and parasitic infections.
  • the polypeptide is modified selectively to provide additional agonists of IL-8.
  • IL-8 agonists may include peptides truncated by 3 amino acid residues at the C terminus by deletion.
  • agonists for IL-8 or other alpha chemokines include cysteine substitutions by aminobutyric acid, homocysteine or diaminosuberic acid.
  • the inventor herein has investigated several low molecular weight peptide analogs of IL-8 with biological activity that substantially compete for IL-8 binding and are based on IL-8 sequences. Truncation of native IL-8, particularly in the C-terminal region thereof, yields IL-8 peptidal mimetics having the therapeutically useful properties of anti-neoplastic and anti-infective drugs. More particularly, the IL-8 low molecular weight peptide analogs of the present invention comprise an amino acid sequence with biological activity substantially equivalent to the IL-8 sequence beginning at residue 4 and continuing through residue 20, wherein at least the N-terminal residues found to be critical for neutrophil binding and stimulation, i.e., Glu-4, Leu-5, Arg-6 are contained at the N-terminal region.
  • IL-8 analogs include an additional two or three residues at the amino terminus of the 20 residue peptide so as to provide the 1-20 forms that are also useful as IL-8 agonists.
  • significant biological activity is associated with low molecular weight peptide analogs from residue 4-17. The resulting in a 13 amino acid peptide also has agonist activity for IL-8.
  • this invention provides a biologically active human IL-8 low molecular weight peptide analog having an amino acid sequence substantially equivalent to the IL-8 polypeptide, beginning at residue 4 and continuing to residue 17 or 20.
  • IL-8 peptide analogs with antagonistic activity have also been synthesized. These peptide analogs are comprised of an amino acid sequence substantially equivalent to those described above, except lacking the N-terminal pair of residues (i.e., Glu-Leu) .
  • the antagonist analogs compete strongly with IL-8 for neutrophil binding without signal transduction, due to the deletion of Glu-Leu (two-thirds of the "ELR" motif required for signal transduction activity) .
  • the peptide comprises the sequence: Arg-Cys-Gln-Cys-Ile-Lys-Thr-Tyr-Ser-Lys- Pro-Phe-His-Pro-Lys as well as similar analogs having either one or two additional N-terminal amino acids.
  • antagonists that compete with IL-8 yet still retain antagonist properties are obtained by replacing residues Glu and Leu with non-polar amino acids, such as Ala, Val or Leu.
  • the IL-8 sequence is truncated from residue 21 to the C-terminus as well at N-terminal residues 1 to 5.
  • the antagonist analogs which contain the N-terminal residues found to be critical for neutrophil binding and stimulation, i.e., Arg 6, begin at residue 6 and continue through residue 20.
  • IL-8 analogs have also been synthesized that include an additional one or two non-polar residues at the amino terminus of the 14 residue peptide so as to provide the 4 or 5-20 forms that are also useful as IL-8 antagonists.
  • significant biological activity is associated with low molecular weight peptide analog from residue 6-17 resulting in a 12 amino acid peptide with antagonist activity for IL-8.
  • this invention also provides a human interleukin-8 low molecular weight peptide analog with antagonist activity having an amino acid sequence substantially equivalent to those found at the N-termini of native IL-8, i.e., amino acids 6 through 20 or 6 through 17. Further, equal or greater activity is associated with the addition of Ala, Val, Leu or other amino acid at residue 4 and 5.
  • This invention also provides methods of use of these agonistic and antagonistic peptide analogs of human IL-8 both in vivo and in vi tro.
  • the embodiments of the present invention are related to low molecular weight peptide analogs of IL-8 which are less than 30, more preferably less than 20, and most preferably 11 to 17 amino acids in length. This shorter length allows for more rapid and extensive tissue distribution of the drug on administration as compared to a 70 amino acid therapeutic. Further, this invention substantially increases the purity of the product through reduced errors inherent to the manufacture of a large protein. In addition, this invention has a significant reduction in the cost of goods as compared to the invention in the aforementioned patent.
  • both sequence and three dimensional, agonists and antagonists for both known and additional alpha chemokines can be derived based on the present invention.
  • the present claims include information on the reduction to practice of an invention specific for the IL-8 ligand and receptor.
  • Figure 1 FACS analysis profiles of Ca + release from polymorphonuclear monocytes (PMNs) , unstimulated (Fig. 1A) or stimulated with native IL-8 (Fig. IB) .
  • PMNs polymorphonuclear monocytes
  • Fig. 1A unstimulated
  • Fig. IB native IL-8
  • FIG. 2 FACS analysis profiles of Ca + release from untreated (Fig. 2A) and PBS treated (Fig. 2B) PMNs.
  • Figure 3 FACS analysis profiles of Ca + release from untreated (Fig. 3A) and analog 1 treated PMNs (Fig. 3B) .
  • FIG. 4A FACS analysis profiles of Ca + release from untreated PMNs (Fig. 4A) and PMNs treated with IL-8 and analog 12.
  • Figure 5 A graph of a dose response curve showing the chemotactic effects of a single i.p. injection of analog 1 in increasing concentrations.
  • X axis represents the dose of analog 1 in ⁇ g/animal;
  • Y axis depicts cell number x 10 6 in the peritoneum.
  • Figure 6 A graph of a dose response curve showing the chemotactic effects of a single i.p. injection of analog 1 in increasing concentrations.
  • X axis represents the dose of analog 1 in ⁇ g/animal;
  • Y axis depicts cell number x 10 6 in the peripheral blood.
  • Figure 7 A graph showing the different cell types present in the peritoneum in response to increasing amounts of i.p. injected analog 1.
  • the X axis represents the dose of analog 1 in ⁇ g/animal;
  • the Y axis represents cell number x 10 6 in the peritoneum. • lymphocytes;
  • Figure 8 A graph showing the absolute cell number of different cell types present in the peritoneum after an i.p. injection of analog 1.
  • the X axis represents the dose of analog 1 in ⁇ g/animal;
  • the Y axis represents cell number x 10 6 in the peritoneum. • lymphocytes; ⁇ PMNs; A monocytes.
  • Figure 9 A graph showing the different cell types present in the peripheral blood after a single i.p. injection of analog 1.
  • the X axis represents the dose of analog 1 in ⁇ g/animal .
  • the ratio of lymphocytes to PMNs is shown on axis Yl; the number of monocytes is shown on Y2. • lymphocytes; ⁇ PMNs; A monocytes.
  • Figure 10 A graph showing the absolute cell number of different cell types present in the peripheral blood after a single i.p. injection of analog 1.
  • the X axis represents the dose of analog 1 in ⁇ g/animal.
  • the ratio of lymphocytes to PMNs is shown on axis Yl; the number of monocytes is shown on Y2. • lymphocytes; ⁇ PMNs; A monocytes.
  • Figure 11 A graph showing the kinetics of the in vivo chemotactic response in the peritoneum following an i.p. injection of 10 ⁇ g of analog 1.
  • the X axis represents time in hours and the Y axis represents the absolute cell number. • lymphocytes; ⁇ PMNs; A monocytes.
  • Figure 12 A graph showing the effects of increasing doses of analog 12 on arachidonic acid induced ear inflammation in mice.
  • the X axis represents increasing doses of analog 12 in ⁇ g/animal .
  • the Y axis represents ear thickness measured in units of .001 inches .
  • Figure 13 Graphs of competitive binding assays showing the ability of peptide analogs to displace radiolabled IL-8 from the IL-8 receptor.
  • the X axis represents increasing molar amounts of analog.
  • the Y axis shows the % of total binding.
  • the analogs tested are as follows: 13A XXR, Sequence I.D. No. 12; 13B CVC, Sequence I.D. No. 23; 13C CMC, Sequence I.D. No. 24; 13D FH, Sequence I.D. No. 25.
  • Figure 14 Graphs of competitive binding assays showing the ability of peptide analogs to displace radiolabled Gro ⁇ from the IL-8 receptor.
  • the X axis represents increasing molar amounts of analog.
  • the Y axis shows the % of total binding.
  • the analogs tested are as follows: 13A XXR, Sequence I.D. No. 12; 13B CVC, Sequence I.D. No. 23; 13C CMC, Sequence I.D. No. 24; 13D FH, Sequence I.D. No. 25.
  • biological activity is a function or set of functions performed by a molecule in a biological context (i.e., in an organism or an in vi tro surrogate or facsimile model) .
  • biological activity is characterized by chemotactic activity (preferably PMNs but may also include T lymphocytes and/or monocytes/macrophages) . It may also include second messenger and/or increases in elastase activity by PMNs.
  • a low molecular weight peptide analog This identifies a natural or mutant (mutated) analog of a protein (generally less then 20-30 residues in length, comprising a linear or discontinuous series of fragments of that protein which may have one or more amino acids replaced with other amino acids and which has altered, enhanced or diminished biological activity when compared with the parent or non-mutated protein.
  • Substantially equivalent biological activity - is that profile of activity which defines IL-8 or other alpha chemokines. In in vitro surrogate models this may include chemotaxis of PMNs, T lymphocytes or monocytes; Ca ++ signal transduction; or increases in elastase activity. In vivo this would be defined as the chemotaxis of PMNs to a localized site for example the peritoneum following i.p. injection or to the peripheral blood.
  • Substantially or essentially equivalent peptide analogs An analog is essentially equivalent to another if it has one or more of the biological activities characteristic of human IL-8, essentially has the same number of amino acids as the analog specified in Tables 2 and 3 with no more than two additions or deletions and, in comparison with the sequence of the specified analog, has at most five amino acid substitutions, all of which would be considered neutral in the art (i.e., acidic for acidic, basic for basic, uncharged polar for uncharged polar, hydrophobic for hydrophobic, and the like) .
  • composition comprising short polypeptide analogs of IL-8 or related alpha chemokines that bind to cellular chemokine receptors and act as agonists or antagonists of IL-8 or other alpha chemokines.
  • polypeptide analogs generally correspond to the amino-terminal domain of IL-8 or related chemokines, as described in greater detail herein.
  • the complete amino acid sequence of naturally- occurring IL-8 has been published (Clark-Lewis et al., J. Biol. Chem. 269: 16075-16078, 1994); the twenty amino acid residues comprising the amino-terminal domain is set forth below as Sequence I.D. No.
  • Asx means Asp or Asn
  • Glx eans Glu or Gin
  • the present invention includes peptide sequences with agonist activity having the following formula:
  • Xaa ! is Gin, Met, or Val; Xaa 2 is lie, or Val; Xaa 3 is Lys, Gin, or Ser; Xaa 4 is Thr, or lie;
  • Xaa 5 is Tyr, Leu, Met, His, Val, or Thr;
  • Xaa 6 is Ser, Gin, Thr, or Ala;
  • Xaa 7 is Lys, Arg, or His;
  • Xaa 8 is absent or is Pro, Phe, or Gly;
  • Xaa 9 is absent or is Phe, He, or Val;
  • Xaa 10 is absent or is His, Lys, or Arg;
  • Xaa n is absent or is Pro, Leu, or Phe; and
  • Xaa 12 is absent or is Lys, His or Arg.
  • Alpha Chemokine - IL-8 also called NAP-1 Glu-Leu-Arg- ⁇ Zys-Gln-Cys-lie-Lys-Thr-Tyr-Ser-Lys-Pro-
  • Analog 5 (Sequence I.D. No. 5) : Derived from Alpha Chemokine - GRO Glu-Leu-Arg-Cys-Gln-Cys-Leu-Gln-Thr-Met-Thr-Gly-Val- His-Leu-Lys
  • Analog 6 (Sequence I.D. No. 6): Derived from Alpha Chemokine - GRO-7 (also called MIP-23)
  • Alpha Chemokine-3 thromboglobulin also called NAP-2
  • Analog 8 (Sequence I.D. No. 8) : Derived from Alpha Chemokine - 9E3
  • Analog 11 Derived from Alpha Chemokine - ENA-78 Glu-Leu-Arg-Cys-Val-Cys-Leu-Gln-Thr-Thr-Gln-Gly-Val- His-Pro-Lys
  • Analog 15 (Sequence I.D. No. 15) : Derived from Alpha Chemokine - GRO-3 (also called MIP-2 ⁇ )
  • Analog 16 (Sequence I.D. No. 16): Derived from Alpha Chemokine - GRO
  • Analog 19 Derived from Alpha Chemokine - 9E3 Arg-Cys-Gln-Cys-Ile-Ser-Thr-His-Ser-Lys-Phe-He-His- Pro-Lys
  • Analog 20 (Sequence I.D. No. 20): Derived from Alpha Chemokine - 310C
  • Analog 21 (Sequence I.D. No. 21) : Derived from Alpha Chemokine - CNC Arg-Cys-Gln-Cys-Leu-Gln-Thr-Val-Ala-Gly-He-His-Phe- Lys Analog 22 (Sequence I.D. No. 22) :
  • CVC Derived from IL-8 (this analog is sometimes referred to herein as "CVC")
  • the present invention includes analogs that are essentially equivalent to any analog of the invention, as specified in Tables 2 and 3.
  • an analog is essentially equivalent to one specified above if it has one or more of the biological activities characteristic of human IL-8, essentially has the same number of amino acids as the analog specified in Tables 2 and 3 with no more than two additions or deletions and, in comparison with the sequence of the specified analog, has at most five amino acid substitutions, all of which would be considered neutral in the art (i.e., acidic for acidic, basic for basic, uncharged polar for uncharged polar, hydrophobic for hydrophobic, and the like) .
  • the acidic amino acids are Asp, Glu and gammacarboxyglutamic acid.
  • the basic amino acids are Arg, Lys, His and Orn.
  • the hydrophobic amino acids are Ala He, Leu, Met, Nor, Phe, Trp, Tyr, Val, t- butylglycine, norvaline, cyclohexylalanine, t- butylalanine, amino-4phenybutyric acid, beta-2-thienylala nine, p-bromophenylalanine, p-chlorophenylalanine, p- iodophenylalanine, p-nitrophenylalanine, 3.5- diiodotyrosine, phenylglycine, and napthylalanine.
  • Uncharged polar amino acids are Asn, Gin, Ser, and Thr. Gly can be substituted for an uncharged polar or a hydrophobic amino acid, but substitutions with Pro are avoided because helical structures may be destabilized by such a significant effect on secondary structure of inserting a Pro in place of another
  • substitutions with Cys are specified and may include substitution with o.-aminobutyric acid (Aba) .
  • This non-natural amino acid is suggested to cause a super-imposition with cysteine. Its ethyl side chain is closer to being isoteric than any of the naturally occurring non-polar amino acids.
  • Cys can be substituted with homocysteine or diaminosuberic acid thereby retaining charge and size conformation but eliminating potential homodimerization.
  • the chiral amino acids of the IL-8 analogs of the present invention have the L configuration.
  • Analog 1 (Sequence I.D. No.
  • Analog 1 was designed as a structural mimic of IL-8 from amino acid residues 4 to 20 (Clark-Lewis et al., 1994, supra).
  • Analog 1 contains overall homology with the amino acid sequence of human IL-8.
  • Analog 2 (Sequence I.D. No. 2) was designated as a structural mimic of human IL-8 from amino acid residues 4 to 17.
  • Analog 2 which has been C-terminally truncated has a slight loss of activity when compared to analog 1.
  • Analog 12 (Sequence I.D. No. 12) was designed as a structural mimic of IL-8 from amino acid residues 6 to 20.
  • Analog 12 contains overall homology with the amino acid sequence of human IL-8.
  • Analogs 13 and 25 (Sequence I.D. Nos. 13 and 25) were designated as structural mimics of human IL-8 from amino acid residues 6 to 17 (or 18) . Analog 13 has been C-terminal truncated causing a slight loss of activity when compared to analog 12.
  • An analog of the present invention can be made by exclusively solid phase techniques, by partial solid- phase techniques, by fragment condensation, by classical solution coupling, or, as long as the analog consists of only amino acids among the twenty naturally occurring amino acids corresponding to codons of the genetic code, by employing recombinant DNA techniques with bacteria, such as E. coli or B . subtilis; yeast, such as S. cerevisiae or P.pastoris; or insect or mammalian cells.
  • IL-8 analogs encompassed by the present invention have one or more of the biological activities of naturally occurring IL-8, as described above, and, as such, are useful therapeutically in one or more of the ways in which IL-8 is known to be useful, e.g., as an anti-infective for bacterial, fungal, viral, and or protozoan infections, as an anti-neoplastic for both leukemia and solid or metastatic disease.
  • the biological activity of an analog of the invention is determined by comparing the analog with naturally occurring IL-8.
  • the analogs of the invention are employed therapeutically, under the guidance of a physician for the treatment of leukemic or solid tumors or metastatic disease and infectious diseases including but not limited to viral, bacterial, fungal, yeast or parasitic. They may also be used for the treatment of anti-inflammatory and auto immune disease. Disorders in this group include SLE, GVHD, RA, IBD, asthma and psoriasis.
  • the dose and dosage regiment of an analog according to the invention that is suitable for administration to a particular patient can be determined by a physician considering the patient's age, sex, weight, general medical condition, and the specific condition and severity thereof for which the analog is being administered.
  • the physician must also determine the route of administration of the analog; the pharmaceutical carrier with which the analog may be combined; and the analog's biological activity, relative to that of naturally occurring human IL-8, in the above- described assays.
  • injection intavenous, subcutaneous or transmuscular
  • injection of 1-500 ⁇ mol of analog/kg body weight
  • bolus injection by bolus injection, by infusion over a period of about 5 minutes to about 60 minutes, or by continuous infusion
  • Aerosol inhalation of 0.1 or 2 mg of analog/kg body weight is also sufficient for efficacy.
  • Intravenous, subcutaneous or intramuscular administration is preferred for use of the analogs of the invention in treatment of neoplastic, infectious, autoimmune or inflammatory diseases.
  • analogs of the invention can be combined, over a wide concentration range (e.g., 0.001 to 11.0 wt %) with any standard pharmaceutical carrier (e.g., physiological saline, THAM solution, or the like) to facilitate administration by any of various routes including intravenous, subcutaneous, intramuscular, oral, or intranasal, including by inhalation.
  • any standard pharmaceutical carrier e.g., physiological saline, THAM solution, or the like
  • compositions of the analogs of the invention can be prepared with any of a variety of inorganic or organic acids, such as for example, sulfuric, phosphoric, hydrochloric, hydrobromic, nitric, citric, succinic, acetic, benzoic and ascorbic.
  • the analogs can, for example, be advantageously converted to the acetate salt by dissolution in an aqueous acetic acid solution (e.g., 10% solution) followed by lyophilization.
  • compositions containing a compound of the present invention as the active ingredient in intimate admixture with a pharmaceutical carrier can be prepared according to conventional pharmaceutical compounding techniques.
  • the carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., intravenous, oral or parenteral.
  • any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like in the case of oral liquid preparations (such as, for example, suspensions, elixirs and solutions) ; or carriers such as starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations (such as, for example, powders, capsules and tablets) . Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form in which case solid pharmaceutical carriers are obviously employed.
  • tablets may be sugar-coated or enteric-coated by standard techniques.
  • the carrier will usually comprise sterile water, though other ingredients, for example, to aid solubility or for preservative purposes, may be included.
  • injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents and the like may be employed.
  • the pharmaceutical compositions will generally contain dosage unit, e.g., tablet, capsule, powder, injection, teaspoonful and the like, from about 0.001 to about 10 mg/kg, and preferably from about 0.01 to about 0.1 mg/kg of the active ingredient.
  • peptides that have a carboxyl group at the carboxy-terminus p-chloromethyl-derivatized polystyrene supports are employed, and the carboxy-terminal amino acid is esterified to the support via reaction with KF.
  • Analogs with a C-terminal proline or a penultimate C- terminal proline may be synthesized using a 2- chlorotrityl chloride derivatized resin. Attachment of FMOC amino acids to the resin can be quantitated by spectrophotometric determination at 266 nm following treatment of a weighed sample with 50% piperidine in DMF. Substitution levels for automated syntheses are preferably between 0.2 and 0.6 mmol amino acid per g resin.
  • FMOC 9-Fluorenyl methoxycarbonyl
  • Side- chain functionalities were protected as follows: Arg with 4-Phenylazobenzyloxycarbonyl; Cys, Gin, and His with trityl; Glu, Ser, and Thr with benzyl; Lys with tertiary butyloxycarbonyl; and Tyr with tertiary butyl.
  • Resins employed in the syntheses were purchased with the C-terminal residue already attached to derivatized polystyrene-1% divinyl-benzene (200-400 mesh) , either by 4-hydroxymethylphenoxyacetic acid or 2- chlorotrityl chloride.
  • NMP N-Methylpyrrolidone
  • HBTU 2 - (lH-benzotriazol-1-yl ) - 1 , 1 , 3 , 3 * tetramethyluronium hexafluorophosphate
  • HPLC buffer systems which may be employed in the analytical HPLC include triethylamine phosphate (TEAP), pH 2.5-3.0, TEAP, pH 6.5, and a mixture of 0.1% phosphoric acid, 0. IM sodium perchlorate, pH 2.5 with an acetonitrile gradient. Although the TFA buffer system does not resolve microheterogeneous contaminants as well as other systems, recovery is generally 50-90% higher. A portion of a fraction from the preparative HPLC which appeared homogenous by analytical HPLC was removed, lyophilized and hydrolyzed for amino acid analysis.
  • Analog 1 peptide-resin and 0.8 g of Analog 12 peptide- resin were obtained. These were added to 10 ml of TFA in two 100 ml round bottom flasks with 500 ⁇ l of H 2 0 500 ⁇ l thioanisole, 250 ⁇ l ethanedithiol and 750 mg phenol and stirred at 25 °C for 2 hours. The reactions were terminated by the addition of 100 ml cold diethyl ether to precipitate the peptides. The solution was filtered and the peptides were extracted with 100 ml 10% acetic acid in water, frozen, and lyophilized.
  • Erythrocytes were removed by 6% dextran sedimentation for 30 minutes at room temperature, and then the supernatant was subjected to Ficoll (Ficoll-Paque, Pharmacia LKB, Uppsala, Sweden) density gradient centrifugation. PMNs were obtained from the pellet. Contaminated erythrocytes were eliminated by one cycle of hypotonic lysis. After an additional washing step, the cells were counted and adjusted to a final concentration of 5xl0 6 /ml in RPMI 1640 (Gibco, Grand Island, NY) .
  • Ficoll Ficoll-Paque, Pharmacia LKB, Uppsala, Sweden
  • Fluo-3 Loading The loading procedure with Fluo-3 (Molecular Probes, Eugene, OR) was carried out with PMNs suspended at a density of 5xl0 6 /ml in fresh RPMI 1640 containing 2.0 ⁇ M Fluo-3 AM (prediluted in dimethyl sulfoxide; Sigma Chemicals) in polypropylene tubes (Falcon 2063, Becton Dickinson) . PMNs were incubated for 25 minutes at 37 °C in a 5% C0 2 incubator. During the incubation period, the PMNs were gently agitated twice.
  • FIG. 1 shows agonist activity on PMNs: Prior studies of IL-8/NAP-1 have demonstrated that this cytokine induces an increase in Ca + after stimulation of neutrophils.
  • Figure IB demonstrates the effect of the 77 amino acid IL-8 at 10 "6 M on neutrophil Ca + release as measured and described above.
  • Figure 1A shows unstimulated neutrophils.
  • Figure 2A again shows unstimulated neutrophils whereas Figure 2B shows the lack of effects by the excipient alone.
  • Treatment with Analog 1 induced a change in neutrophil Ca + concentration as shown in Figure 3B relative to untreated cells in Figure 3A. The data show that the majority of neutrophils showed an essentially identical increase in calcium concentration upon addition of either IL-8/NAP-1 or Analog 1.
  • Analog 12 exhibits antagonist activity on PMNs: As shown in figure IB, treatment of neutrophils with native IL-8/NAP-1 leads to an increase of arbitrary fluorescence units as compared to excipient treated Fluo-3 loaded neutrophils (figure 2B) . However, as shown in Figure 4B, when the PMN's were pre-incubated with both native IL-8 and analog 12 at 10 "6 M, analog 12 blocked the appearance of the Ca + signal induced by IL-8 as shown in Figure IB.
  • mice used for the study were C57BL/6 females, which were obtained from Jackson Laboratories. The animals were 8-10 weeks of age and weighed 15-18g. The mice were housed in conventional cages, fed pelleted food and given water ad libi tum.
  • mice were bled from the retinal orbital plexus and the blood (40 ⁇ l) was collected into heparinized capillary tubes. The blood was then analyzed using a Serona Baker 9000 Blood analyzer. In addition, blood films were made and differentials undertaken on at least 200 cells/sample.
  • mice were sacrificed by ether overdose, the ventral skin reflected and the peritoneum lavaged with three 5 ml lavages of calcium-, magnesium-free HBSS. At one, two, four, eight and 24 hours, following injection, three to five mice and/or control mice were lavaged and the cells collected in 15 ml tubes. The peritoneal cells were then centrifuged and counted. In addition, a differential was done on the peritoneal cells in a cytospin preparation. For the cytospin, 25 ⁇ l of bovine albumin (Sigma Lot #70H0183) was first placed in the bottom of the chamber, and 100 ⁇ l of cell suspension (100,000 cells) added.
  • bovine albumin Sigma Lot #70H0183
  • the chambers were spun at 1000 rpm for 5 minutes and left to dry. They were then placed in leukostat fixative solution for 5 seconds followed by 45 seconds in Leukostat solution 1 and 45 seconds in Leukostat solution 2. Fixed cells were washed in deionized H 2 0 for 5 seconds and allowed to dry. The slides were analyzed under a microscope for differentials.
  • Analog 1 is an agonist with biological activity in in vivo assays.
  • the in vivo chemotactic activity for cells into both the peritoneum and PBL are shown in this data set.
  • Figure 5 shows the effect of a single i.p. injection of Analog 1 on peritoneal cellularity when employed in increasing concentrations from 0.1-500 ⁇ g/animal. Optimal activity was observed at 10 ⁇ g/animal.
  • a significant increase in PBL cellularity ( Figure 6) was observed with maximal activity at 0.1 and 10 ⁇ g/animal.
  • the primary cell type elicited in the peritoneum by the i.p. injection of Analog 1 was PMNs as shown in Figure 7.
  • Analog 1 Treatment with Analog 1 resulted in a four-fold increase in PMNs in the peritoneum and an almost two-fold increase in monocyte/macrophages (Figure 8) . Similarly, there was an increase in the frequency of PMNs in the peripheral blood ( Figure 9) with a concomitant significant increase in the absolute number of PMNs and monocytes in the peripheral blood ( Figure 10) .
  • Figure 11 shows the kinetics of the in vivo chemotactic response in the peritoneum following i.p. injection of 10 ⁇ g of this peptidal low molecular weight analog. As mentioned previously, the greatest increase observed was in the number of macrophages and PMNs in the peritoneum.
  • IL-8 induced a neutrophil accumulation that was fast in onset, relatively short in duration and was associated with a parallel time course of plasma protein extravasation (Rampart, M. , Am. J. Pathol. 135-.21-25, 1989).
  • the polypeptide Analog 1 of the present invention elicits essentially the same biological responses in vivo as naturally-occurring IL-8.
  • Analog 12 (Sequence I.D. No. 12) was prepared in D-PBS.
  • Analog 12 consists of 88.1% active peptide and the calculations were adjusted to compensate for the activity of Analog 12.
  • Serial dilutions were then made resulting in solutions of appropriate doses of analog 12 in 0.2 ml.
  • the animals were injected intraperitoneally with 0.2 ml of the appropriate solution 1 hour prior to arachidonic acid application.
  • the study consisted of various dosage groups as well as excipient groups as contols.
  • mice C57BL/6 females, which were obtained from Jackson Laboratories (age 8 weeks and weight 15-18g) .
  • the mice were housed in conventional cages, fed pelleted food and given water ad libi tum.
  • the arachidonic acid (Sigma Lot #42H7817) was dissolved in methyl alcohol resulting in a final concentration of 2 mg/20 ⁇ l. At time zero, 10 ⁇ l of arachidonic acid was applied to each side of the test ear using a pipettor. Each mouse received a total of 2 mg and a total volume of 20 ⁇ l. One hour post challenge, the test and control ears were measured for thickness using a Mitutoyo No. 7300 gauge caliper. The thickness was recorded in units of 0.001 inches. To determine the total edema, the measurement of the control ear was subtracted from the test ear measurement (arachidonic acid ear) .
  • Analog 12 is an antagonist with in vivo bioactivity.
  • the effect of Analog 12 on arachidonic acid-induced ear inflammation was evaluated in vivo .
  • the application of arachidonic acid to the pinna of mice induces an immediate PMN-associated erythema and edema which may be measured by change in thickness.
  • the administration of Analog 12 blocked edema with an approximate EC-50 of 1 ⁇ g/animal.
  • NSAID phenidone
  • Chemokines form a superfamily that is divided into two distinct functional classes: alpha and beta. All the members of each class share an organizing primary sequence motif. Alpha family members are distinguished by the C-X-C motif - where the first two cysteines of the motif are separated by an intervening residue. C-X-C chemokines are potent chemoattractants and activators for neutrophils. The beta family chemokines have a C-C motif and are equally potent chemoattractants and activators of monocytes. However, other roles are rapidly emerging for chemokines as well. Thus, both alpha and beta chemokines, have been shown to attract both memory T-cell and eosinophils as well as trigger the release of histamine from basophils. Edgington, discussed (Edgington et al. ,
  • Receptor promiscuity presents one problem to drug design of the chemokines.
  • individual receptors bind multiple ligands. Determining chemokine structure and function after dispensing with the dogma of "one ligand, one receptor" is extremely difficult, especially when target cells contain an ensemble of receptors on their membrane.
  • chemokine receptors involved in binding the beta chemokines MCP-1, MlP-l ⁇ / 1 and RANTES. Based on studies to date, one receptor binds all three ligands, another binds only MIP- l / ⁇ and a third only binds MCP-1. Similar observations of receptor/1igand promiscuity are seen with the alpha chemokines.
  • Type A receptors have a high affinity for IL-8 and low affinity for MGSA and NAP-2.
  • the type B receptors bind IL-8 and MGSA with high and NAP-2 with intermediate affinity.
  • DNA sequence data and X-ray diffraction data will facilitate rational drug design. Based on this knowledge, efficacious peptide analogs can be synthesized and assayed in the assays specified herein.
  • Platelet factor 4 is carried within the alpha granules of platelets in the form of a non-covalent complex.
  • PF-4 is a tetramer of four identical polypeptide chains, each of which contains 70 residues in the human moieties.
  • white blood cells i.e., neutrophils and monocytes and it's release may be a signal that is involved in inflammation.
  • Other possible functions of PF-4 derive from a strong binding to negatively charged polysaccharides especially heparan and heparin for which it has a dissociation constant of 10 "7-5 .
  • the ability of PF-4 to neutralize heparin and related polymers is of general interest because heparin has been shown to interact with over 50 different enzymes to suppress muscle growth and to accelerate angiogenesis in solid tumors.
  • PF-4 has recently been patented as
  • Oncostatin A for its ability to inhibit tumor growth. It has also been shown to reverse immunosuppression in mice.
  • PF-4 also binds tightly and preferentially to double stranded DNA in vi tro. This binding probably does not occur in vivo but it might be an important attribute of several recently discovered growth related proteins which are homologous to PF-4.
  • Members of this class are 1) induced by IFN- ⁇ , 2) constitutively overexpressed in Chinese hamster and human cell lines, 3) strongly induced by Rous sarcoma virus and fibroblast cells and 4) over expressed in stimulated leukocytes.
  • PF-4 does not induce comparable neutrophil responses although chemotaxis and exocytosis have been reported with concentrations that were 1,000 to 10,000- fold higher than those required for IL-8.
  • PF-4 crystallizes as a tetramer, although the monomer structure is similar to that of IL-8.
  • human PF-4 is in equilibrium among monomers, dimers, and tetramers.
  • PF-4 and IL-8 share 35% sequence identity, including the four cysteines.
  • Molecular modeling studies suggest that a similar folding pattern will be found for all members of the C-X-C family. Even MCP which belongs to the C-C family (beta chemokine) , has been found to have the same tertiary structure. Thus, it will be possible to sequence an agonist for PF4 in accordance with the present invention.
  • Platelet basic protein is a highly specific platelet alpha granular protein that is a precursor of low affinity platelet factor 4 (LA-PF4) and beta thromboglobulin (3TG) . These proteins differ only in amino terminal amino acid sequence and isoelectric point. PBP is synthesized by megakaryocytes, contains 94 amino acids and is converted to LA-PF4 which contains 85 amino acid residues within megakaryocyte and platelet granules. jSTG itself (81 amino acid residues) as originally described cannot be detected in cell lysates prepared using trichloroacetic acid. It probably results from amino terminal cleavage of LA-PF4 or PBP after cell secretion.
  • LA-PF4 low affinity platelet factor 4
  • 3TG beta thromboglobulin
  • LA-PF4 also referred to as connective tissue activating peptide III (CTAP-III)] is a weak mitogen for connective tissue fibroblasts. It has also been reported that 3TG antigen promotes chemotaxis in fibroblasts.
  • NAP-2 neutrophil activating peptide
  • NAP-2 is a 78 amino acid peptide corresponding to the major carboxy-terminal fragment of 0TG. It has 46% homology with NAP-l/IL-8. NAP-2 behaves as a typical chemotactic receptor agonist, inducing cytosolic free Ca + changes, chemotaxis, and exocytosis while PBB, LA-PF4 and PF4 have little such activity. It should be noted, as discussed above, that NAP-2 also interacts with the NAP-l/IL-8 receptors. Thus, in accordance with the present invention, it should be possible to synthesize agonists for NAP-2, including those that bind to the IL-8 beta receptor. EXAMPLE VIII
  • IP-10 was originally isolated as a predominant messenger RNA form induced by IFN- ⁇ or LPS in monocytes and its expression has been detected in vivo during the development of a delayed type hypersensitivity cellular immune response by monocytes, endothelial cells, and infiltrating mononuclear cells. In addition, IP-10 expression has been seen in the epidermis, dermis and cutaneous lesions of psoriasis, tuberculoid leprosy, and fixed drug eruptions.
  • IP-10 is a member of the chemokine superfamily and is approximately 30% homologous to IL-8 and PF-4. Recent studies have shown that IP-10 can elicit an anti- tumor inflammatory response that is capable of inhibiting the growth of plasmacytoma and mammary adenocarcinoma in immunocompetent mice. This effect is thymus dependent suggesting that IP-10 might act on T-cells. In addition, a neutrophil, and monocytic accumulation is seen as a result of IP-10 expression in immunocompetent but not nude mice. IP-10 does not have an ELR motif. ELR incorporation into IP-10 is not sufficient for IL-8 receptor interaction or neutrophil activation and suggests that IP-10 has a different receptor ligand conformation. However, hybrids formed between IL-8 and IP-10 could be designed which demonstrate that essential receptor binding motifs from the IL-8 sequence could be structured within the IP-10 molecule allowing IL-8 binding.
  • IP-10 is expressed by activated but not by resting T-hybridoma cells, normal T-cells and thymocytes. While resting lymphocytes did not synthesize IP-10, a high level of IP- 10 transcripts are found in lymphoid organs (spleen, thymus, and lymph nodes) . Thymic and splenic stromal cells constitutively express high levels of both IP-10 messenger RNA and protein accounting for the high level of spontaneous expression in lymphoid tissue. Therefore, in addition to its role as a pro-inflammatory cytokine, IP-10 may participate in T-cell effector function of perhaps T-cell development. IP-10 expression has also been shown to be induced in delayed type contact hypersensitivity in sensitized animals. Thus, in accordance with present invention, we will be able to synthesize agonists for IP-10.
  • GRO-ot which is also termed "melanoma growth stimulatory" activity.
  • GRO- ⁇ r is expressed in human colon tumors along with GRO-3 and GRO-7.
  • GRO- * and GRO-7 show 90 and 86% sequence homology with GRO- ⁇ .
  • the GRO- ⁇ /MGSA alpha chemokine has potent chemotactic, growth regulatory and transformative functions.
  • the function of GR0-3 and GRO-7 is unknown.
  • GRO- ⁇ messenger RNA is selectively overexpressed in psoriasic epidermis and is reduced by therapy with Cyclosporin-A. It has been suggested that this over expression is a karyotinocyte response to activated T-cells in psoriasis.
  • GRO- ⁇ /MGSA has been localized in a variety of cutaneous lesions. A raised level of immunoreactive GRO- ⁇ MGSA in diseased epidermis is detected in verruca vulgaris followed by psoriasis, keratoacanthoma, and squamous cell carcinoma. Detection of GRO-ot in basal cell carcinoma is variably present in the sclerosis variant and absent in the more common nodular variant.
  • ENA-78 epidermal cell derived neutrophil activator
  • ENA-78 shows significant amino acid sequence homology with NAP-2 (53%) , GRO- ⁇ (52%) , and IL-8 (22%) .
  • ENA-78 appears to activate neutrophils through the IL-8 receptor.
  • ENA-78 has been cloned in pigs and was initially described as alveolar macrophage derived chemotactic factor 2. It shares 53% sequence homology with human NAP-2 and 61% sequence homology with the GRO-related proteins. It also has 67% sequence homology with the 78 amino acid ENA-78 and is felt to represent the porcine variant thereof.
  • ENA-78 was initially identified in the conditioned medium of stimulated human epithelial cell line A549. It is produced in response to stimulation with either IL-13 or TNF- ⁇ and is produced and secreted concomitantly with IL- 8, GRO- ⁇ , and GRO-7.
  • ENA-78 consists of 78 amino acids and has a molecular weight of 8357. The four cysteines are positioned identically to those of IL-8 and similar analogues.
  • ENA-78 stimulates neutrophils, induces chemotaxis, a rise in intracellular-free Ca + and exocytosis. Cross desensitization experiments indicate that ENA-78 acts through the same type of receptors as IL-8, NAP-2 and GRO- ⁇ .
  • Recombinant human IL-8 was obtained from Bachem and radioiodinated with IODOGEN, (Pierce, IL) . Following purification by column chromatography, the radioligand was used in competitive binding assays using non- radiolabeled peptide analogs of the present invention. Analogs with the following sequences were synthesized and used as competitors. Parallel competitive binding studies were performed with the same analogs using another radiolabeled chemokine, Gro- ⁇ . The analogs used for this Example include Analogs 12 and 23-25, Sequence I.D. Nos. 12, 23, 24, 25) and were synthesized according to procedures set forth in Example 1.
  • Analog 12 (Sequence I.D. No. 12) : Derived from IL-8 (this analog is sometimes referred to as "XXR")
  • Analog 23 (Sequence I.D. No. 23): Derived from IL-8 (this analog is sometimes referred to herein as "CVC")
  • Analog 25 (Sequence I.D. No. 25): Derived from IL-8 (this analog is sometimes referred to as "FH")
  • the agonistic peptide analogs of the invention can act as immunostimulants in a manner similar to naturally occurring alpha chemokines, and may be useful as a protective agent for the immune system during chemotherapy and radiation therapy. Experiments were performed to determine if treatment of animals with Analog 1 could confer protection from myelosuppressive doses of gamma irradiation.
  • mice C57BL/6 females, which were obtained from Jackson Laboratories (age 8 weeks and weight 15-18g) .
  • the mice were housed in conventional cages, fed pelleted food and given water ad libitum.
  • mice were administered Analog 1 continuously at a rate of 1 ⁇ l/mouse over a 24- hour period. During that time they were administered a dosage of 700 rads of gamma radiation from a cobalt source. Mice that received the Analog 1 treatment exhibited accelerated myeloid restoration following irradiation, as compared to mice that received a treatment of excipient only.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des analogues polypeptidiques dérivés de l'interleukine-8. Dans une forme d'exécution, ces réactifs agissent comme agonistes des alpha-chémokines et sont utiles comme composés chimiothérapeutiques pour le traitement de néoplasmes, en particulier des tumeurs solides et des leucémies. Ils peuvent également être efficaces pour le traitement de maladies infectieuses médiées par des micro-organismes, tels que des bactéries, des champignons ou des virus. Dans une autre forme d'exécution, ces analogues peptidiques ont une activité d'antagonistes vis-à-vis des alpha-chémokines et ils peuvent donc être utilisés comme agents anti-inflammatoires, ainsi que pour le traitement de maladies auto-immunes et de différents états inflammatoires chroniques, tels que la polyarthrite rhumatoïde et le psoriasis.
PCT/US1995/012099 1994-09-23 1995-09-22 Agonistes et antagonistes polypeptidiques de l'interleukine-8 humaine WO1996009062A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU36817/95A AU3681795A (en) 1994-09-23 1995-09-22 Polypeptide agonists and antagonists of human interleukin-8

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US31138094A 1994-09-23 1994-09-23
US08/311,307 1994-09-23
US08/311,307 US5627156A (en) 1994-09-23 1994-09-23 Polypeptide agonists for human interleukin-8
US08/311,380 1994-09-23

Publications (1)

Publication Number Publication Date
WO1996009062A1 true WO1996009062A1 (fr) 1996-03-28

Family

ID=26977840

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/012099 WO1996009062A1 (fr) 1994-09-23 1995-09-22 Agonistes et antagonistes polypeptidiques de l'interleukine-8 humaine

Country Status (2)

Country Link
AU (1) AU3681795A (fr)
WO (1) WO1996009062A1 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997000893A1 (fr) * 1995-06-20 1997-01-09 Chiron Corporation Composes liant le recepteur de l'interleukine 8
WO1998001150A1 (fr) * 1996-07-05 1998-01-15 Virocell, Inc. Interleukine 8 utilisee comme agent antiviral ou anticancereux
EP0807439A3 (fr) * 1996-05-14 1998-03-11 Smithkline Beecham Corporation Procede de traitement de la septicemie et du syndrome de detresse respiratoire chez l'adulte
US6174995B1 (en) 1994-08-23 2001-01-16 Haodong Li Human chemokines, CKβ4 and CKβ10/MCP-4
US6391589B1 (en) 1994-08-23 2002-05-21 Human Genome Sciences, Inc. Human chemokine beta-10 mutant polypeptides
WO2001072830A3 (fr) * 2000-03-31 2002-06-20 Ipf Pharmaceuticals Gmbh Medicament et moyen diagnostique pour analyser le proteome de surface de cellules tumorales et inflammatoires, et pour traiter des maladies tumorales et inflammatoires, de preference au moyen d'une analyse specifique des recepteurs de chimiokines et de l'interaction de ligands recepteurs de chimiokines
US6458349B1 (en) 1995-06-02 2002-10-01 Human Genome Sciences, Inc. Chemokine β-4 polypeptides
WO2005040210A3 (fr) * 2003-10-22 2005-06-23 Applied Research Systems Nouveaux antagonistes de la cxcl8
WO2006101439A1 (fr) * 2005-03-23 2006-09-28 Astrazeneca Ab Criblage
US7375192B2 (en) 2002-05-01 2008-05-20 Human Genome Sciences, Inc. Antibodies that specifically bind to chemokine beta-4
US9133273B2 (en) 2010-11-19 2015-09-15 Eisai R&D Management Co., Ltd. Nucleic acids encoding neutralizing anti-CCL20 antibodies

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5079228A (en) * 1990-02-05 1992-01-07 Board Of Regents, The University Of Texas System Peptide inhibitors of neutrophil activating factor induced chemotaxis
WO1992004372A1 (fr) * 1990-09-12 1992-03-19 The Scripps Research Institute Site actif d'interleukine-8 : analogues polypeptidiques et anticorps
WO1993011159A1 (fr) * 1991-12-04 1993-06-10 The Biomedical Research Centre Limited Analogues de l'interleukine-8 humaine
US5234911A (en) * 1990-07-09 1993-08-10 Gist-Brocades, N.V. Substance with interleukin-8 inhibiting activity and process for its preparation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5079228A (en) * 1990-02-05 1992-01-07 Board Of Regents, The University Of Texas System Peptide inhibitors of neutrophil activating factor induced chemotaxis
US5234911A (en) * 1990-07-09 1993-08-10 Gist-Brocades, N.V. Substance with interleukin-8 inhibiting activity and process for its preparation
WO1992004372A1 (fr) * 1990-09-12 1992-03-19 The Scripps Research Institute Site actif d'interleukine-8 : analogues polypeptidiques et anticorps
WO1993011159A1 (fr) * 1991-12-04 1993-06-10 The Biomedical Research Centre Limited Analogues de l'interleukine-8 humaine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
THE JOURNAL OF BIOLOGICAL CHEMISTRY, Volume 269, Number 23, issued 10 June 1994, CLARK-LEWIS et al., "Structural Requirements for Interleukin-8 Function Identified by Design of Analogs and CXC Chemokine Hybrids", pages 16075-16081. *

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138498B2 (en) 1994-08-23 2006-11-21 Human Genome Sciences, Inc. Antibodies to MCP-4
US7183081B2 (en) 1994-08-23 2007-02-27 Human Genome Sciences, Inc. Human Ckβ-10 polynucleotides
US6921645B2 (en) 1994-08-23 2005-07-26 Human Genome Sciences, Inc. Antibodies to chemokine β-4
US6673344B1 (en) 1994-08-23 2004-01-06 Human Genome Sciences, Inc. Antibodies to human CKβ-10/MCP-4
US6391589B1 (en) 1994-08-23 2002-05-21 Human Genome Sciences, Inc. Human chemokine beta-10 mutant polypeptides
US6174995B1 (en) 1994-08-23 2001-01-16 Haodong Li Human chemokines, CKβ4 and CKβ10/MCP-4
US6458349B1 (en) 1995-06-02 2002-10-01 Human Genome Sciences, Inc. Chemokine β-4 polypeptides
WO1997000893A1 (fr) * 1995-06-20 1997-01-09 Chiron Corporation Composes liant le recepteur de l'interleukine 8
EP0807439A3 (fr) * 1996-05-14 1998-03-11 Smithkline Beecham Corporation Procede de traitement de la septicemie et du syndrome de detresse respiratoire chez l'adulte
US6406688B1 (en) 1996-05-14 2002-06-18 Human Genome Sciences, Inc. Method of treating sepsis and ARDS with chemokine β-4
US6290948B1 (en) * 1996-05-14 2001-09-18 Smithkline Beecham Corporation Method of treating sepsis and ARDS using chamohine beta-10
AU713675B2 (en) * 1996-07-05 1999-12-09 Virocell Inc. Interleukin-8 as an antiviral and antitumor agent
WO1998001150A1 (fr) * 1996-07-05 1998-01-15 Virocell, Inc. Interleukine 8 utilisee comme agent antiviral ou anticancereux
US5900235A (en) * 1996-07-05 1999-05-04 Virocell Inc. Interleukin-8 as an antiviral and antitumor agent
WO2001072830A3 (fr) * 2000-03-31 2002-06-20 Ipf Pharmaceuticals Gmbh Medicament et moyen diagnostique pour analyser le proteome de surface de cellules tumorales et inflammatoires, et pour traiter des maladies tumorales et inflammatoires, de preference au moyen d'une analyse specifique des recepteurs de chimiokines et de l'interaction de ligands recepteurs de chimiokines
US7375192B2 (en) 2002-05-01 2008-05-20 Human Genome Sciences, Inc. Antibodies that specifically bind to chemokine beta-4
US7943741B2 (en) 2002-05-01 2011-05-17 Human Genome Sciences, Inc. Antibodies that specifically bind to chemokine β-4
JP2007533300A (ja) * 2003-10-22 2007-11-22 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 新規のｃｘｃｌ８アンタゴニスト
WO2005040210A3 (fr) * 2003-10-22 2005-06-23 Applied Research Systems Nouveaux antagonistes de la cxcl8
WO2006101439A1 (fr) * 2005-03-23 2006-09-28 Astrazeneca Ab Criblage
US9133273B2 (en) 2010-11-19 2015-09-15 Eisai R&D Management Co., Ltd. Nucleic acids encoding neutralizing anti-CCL20 antibodies
US9809647B2 (en) 2010-11-19 2017-11-07 Eisai R&D Management Co., Ltd. Neutralizing anti-CCL20 antibodies

Also Published As

Publication number Publication date
AU3681795A (en) 1996-04-09

Similar Documents

Publication Publication Date Title
WO1993009799A1 (fr) Supression de la megacaryocytopoïese a l'aide de proteines inflammatoires de macrophages
US20110076234A1 (en) Peptides comprising an isodgr motif
US5795859A (en) Peptide which abrogates TNF and/or LPS toxicity
US20070160574A1 (en) Design of CXC chemokine analogs for the treatment of human diseases
US5877276A (en) Polypeptide agonists for human interleukin-8
US6447766B1 (en) Method of mobilizing hematopoietic stem cells
WO1996009062A1 (fr) Agonistes et antagonistes polypeptidiques de l'interleukine-8 humaine
US5627156A (en) Polypeptide agonists for human interleukin-8
KR101477767B1 (ko) Ｐｆ４와 ｒａｎｔｅｓ 간의 상호작용에 대한 길항제
US5912232A (en) Anti-inflammatory polypeptide antagonists of human I1-8
WO1993009794A1 (fr) Suppression de megacaryocytopoiese par le peptide d'activation de neutrophile-2
US5587457A (en) Neutrophil stimulating peptides
WO2008152508A2 (fr) Conjugué cytokinique
US6375928B1 (en) Neutrophil stimulating peptides
Rathjen et al. Differential effects of small tumour necrosis factor-alpha peptides on tumour cell cytotoxicity, neutrophil activation and endothelial cell procoagulant activity
US6107273A (en) Tumor necrosis factor inhibitors
WO1993006128A1 (fr) Peptides antagonistes du facteur de necrose tumorale
EP0519976A1 (fr) Peptides stimulant les polynucleaires neutrophiles.
EP0521918A1 (fr) Peptides a action anti-tumorale
AU673332C (en) Peptide which abrogates TNF and/or LPS toxicity
EP1033997B1 (fr) Technique visant a mobiliser des cellules souches hematopoietiques
AU676842B2 (en) Neutrophil stimulating peptides
AU684539B2 (en) Macrophage inflammatory proteins-3, -4 and -1 Gamma
AU7467391A (en) Anti-tumour peptides
CA2178927A1 (fr) Inhibiteurs peptidiques de molecules de la famille des intercrines cxc

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA